Trial Profile

DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gedatolisib (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Endometrial cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Focus Adverse reactions

Most Recent Events

15 Jul 2021 Following the first 9 patients treated with the above mentioned schedule, the study was amended, dose of Gedatolisib 110mg and 130 mg has added in the treatment.
15 Jul 2021 Results published in the Clinical Cancer Research
21 Sep 2020 According to results presented at the 45th European Society for Medical Oncology Congress, Carboplatin was initially administered at AUC5 on day 8 and Paclitaxel at 80 mg/m2 on day 8, 15 and 22 and after a protocol amendment on day 1 and day 1, 8 and 15 respectively, in 28d cycles.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com